MedTrace Logo

N-Acetylcysteine for Patients With COPD and Chronic Bronchitis

NCT01739790 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-09-13

Study results available
· View outcomes & findings →

Summary

N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive lung disease (COPD), particularly for those who have accompanying symptoms of chronic cough and sputum production. Compared to placebo, high-dose NAC will improve Saint George Respiratory Questionnaire scores in patients with COPD and chronic bronchitis.

Conditions

  • COPD
  • Chronic Bronchitis

Interventions

DRUG

N-Acetylcysteine

1800 mg twice daily for 8 weeks

DRUG

Placebo

Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.

Sponsors & Collaborators

Principal Investigators

  • Dennis E Niewoehner, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01739790 on ClinicalTrials.gov